Market research
SNCA Seneca Biopharma, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 26
- Dividend yield
- Not available
- Beta
- 1.88
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US81689B1035
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 26
- Dividend yield
- Not available
- Beta
- 1.88
About
About Seneca Biopharma, Inc
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SNCA discussion.
5 years, 4 months ago
Seneca Biopharma, Inc is currently in a long term uptrend where the price is trading 146.3% above its 200 day moving average.
From a valuation standpoint, the stock is 37.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1846.5.
Seneca Biopharma, Inc's total revenue sank by 0.0% to $2K since the same quarter in the previous year.
Its net income has increased by 99.8% to $-4K since the same quarter in the previous year.
Finally, its free cash flow fell by 7.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Seneca Biopharma, Inc gets an overall score of 2/5.